1. Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report
- Author
-
Sara Merler, Sarah Pafumi, Ilaria Zampiva, Francesca Zacchi, Stefano Manduca, Emanuela Fantinel, Andrea Zivi, and Michele Milella
- Subjects
Male ,Pharmacology ,Carcinoma, Transitional Cell ,Cancer Research ,Urinary Bladder Neoplasms ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Pharmacology (medical) ,Deoxycytidine ,Gemcitabine - Abstract
Therapeutic alternatives in advanced urothelial carcinoma are limited, especially in advanced lines, with only a few drugs having demonstrated relevant clinical benefit. This article discusses about a young patient with significant cardiovascular comorbidities, already treated with recommended first- and second-line drugs, and suffering from liver metastases. Despite the known poor prognosis of this disease and the few supporting data, given his peculiar clinical history, we opted to treat him with a third-line gemcitabine rechallenge with a notable response on his liver lesions. We present an intriguing case, both in terms of the therapeutic sequence and the disease course.
- Published
- 2022
- Full Text
- View/download PDF